SCHIZOPHRENIA
Approximately 74% of all Schizophrenia patients terminate therapy within the first 18 months using the current therapies. The high level of side effects is the main reason for discontinuation of the therapy.
Cannabidiol (CBD), a major constituent of Cannabis sativa L., has been found to be anxiolytic and to have antipsychotic properties, and may be neuroprotective in humans.
ECP012A in Schizophrenia
Echo Pharmaceuticals is currently developing a new dosage form with Cannabidiol (CBD), ECP012A, which will be tested in Schizophrenia patients for the prevention of psychosis.